title: Stability of an ophthalmic micellar formulation of cyclosporine A in unopened multidose eyedroppers and in simulated use conditions.
abstract: Cyclosporine A eye drops are used at concentrations ranging from 0.5 to 20mg/mL to treat a variety of ophthalmic diseases. Cyclosporine A formulations at high concentrations are difficult to manufacture because of cyclosporine's lipophilicity, and generally require an oil based vector. In this study, we investigated the physicochemical and microbiological stability of two high concentrations (10mg/mL and 20mg/mL) of an ophthalmic cyclosporine A micellar solution in a low density polyethylene multidose eyedropper, at two conservation conditions (5°C and 25°C), before and with simulated use. Analyses used were the following: visual inspection, cyclosporine quantification by a stability-indicating liquid chromatography method, osmolality and pH measurements and turbidity. A complementary analysis by dynamic light scattering was implemented to evaluate potential particle formation or micelle size change. In the in-use study, cyclosporine quantification was also performed on the drops emitted from the multidose eyedroppers. Our results show that the cyclosporine micellar formulation retains good physicochemical and microbiological stability, as all parameters stayed within acceptable range limits, however a higher variability in cyclosporine concentrations was observed for 20mg/mL units stored at 25°C. The in-use study showed that cyclosporine concentrations in the emitted drops were also within acceptable range limits. The micellar formulation presented in this study can therefore be stored at 5°C or at ≤25°C for up to 6months.
authors.affiliation: Universite Clermont Auvergne, Chu Clermont Ferrand, CNRS, Sigma Clermont, ICCF, F-63000 Clermont-Ferrand, France. Electronic address: pchennell@chu-clermontferrand.fr.
authors.forename: P
authors.initials: P
authors.lastname: Chennell
authors.affiliation: Chu Clermont-Ferrand, Pole Pharmacie, F-63000 Clermont-Ferrand, France.
authors.forename: L
authors.initials: L
authors.lastname: Delaborde
authors.affiliation: Chu Clermont-Ferrand, Pole Pharmacie, F-63000 Clermont-Ferrand, France.
authors.forename: M
authors.initials: M
authors.lastname: Wasiak
authors.affiliation: Chu Clermont-Ferrand, Pole Pharmacie, F-63000 Clermont-Ferrand, France.
authors.forename: M
authors.initials: M
authors.lastname: Jouannet
authors.affiliation: Universite Clermont Auvergne, Chu Clermont Ferrand, CNRS, Sigma Clermont, ICCF, F-63000 Clermont-Ferrand, France.
authors.forename: E
authors.initials: E
authors.lastname: Feschet-Chassot
authors.affiliation: Chu Clermont-Ferrand, Service Ophtalmologie, F-63000 Clermont-Ferrand, France.
authors.forename: F
authors.initials: F
authors.lastname: Chiambaretta
authors.affiliation: Universite Clermont Auvergne, Chu Clermont Ferrand, CNRS, Sigma Clermont, ICCF, F-63000 Clermont-Ferrand, France.
authors.forename: V
authors.initials: V
authors.lastname: Sautou
mesh_terms: D002626:Chemistry, Pharmaceutical; D016572:Cyclosporine / Q000737:chemistry*; D004355:Drug Stability; D007166:Immunosuppressive Agents / Q000737:chemistry*; D008823:Micelles; D009883:Ophthalmic Solutions; D013696:Temperature; D014783:Viscosity
chemical_list: D007166:Immunosuppressive Agents; D008823:Micelles; D009883:Ophthalmic Solutions; D016572:Cyclosporine
keywords: Cyclosporine A; Drug preparation; Drug stability; Ophthalmic; Pharmaceutical technology